SOUTHLAKE, Texas--(BUSINESS WIRE)--HeartSciences, an innovative medical device company, announced today that an abstract describing the detection of cardiac mechanical relaxation abnormalities using a 12-lead resting ECG that incorporates wavelet signal processing has been selected for a poster presentation at 2018 American College of Cardiology Scientific Sessions.
Details of presentation are as follows:
Poster Title: Prediction of Cardiac Mechanical Relaxation Abnormalities from Surface ECG Wavelets
Date: Sunday, March 11, 2018 at 3:45 p.m.
Location: Orange County Convention Center | 9800 International Drive | Orlando, Florida 32819 USA | Hall A/B
HeartSciences will participate in the Future Hub at ACC 2018. Future Hub is a multi-vendor educational venue to inform, educate and inspire ACC 2018 attendees by exposing them to the latest innovations in Digital Health, Medical Devices, and Ed Tech (Educational Technology). HeartSciences will be located at space FH7 of the Future Hub to present the MyoVista® spECG™ technology.
HeartSciences is advancing the field of electrocardiography through the latest research in heart disease in combination with the application of the latest technology. HeartSciences applies wavelet signal processing and artificial intelligence to develop breakthrough ECG technology. Wavelet signal processing is used in many different industries as a valuable tool that provides insights and new valuable data related to spectral analysis of a signal.
HeartSciences’ MyoVista spECG Cardiac Testing Device is a new 12-lead resting electrocardiograph utilizing continuous wavelet transform (CWT) based signal processing. Proprietary informatics focus on energy related information rather than conventional voltage-based information and provide valuable new data to assist in identifying abnormalities.
Proprietary informatics provided through signal processing include:
- MyoVista Energy Waveform - Displays the energy distribution in the acquired ECG signal after transformation using continuous wavelet transform mathematics.
- MyoVista Ventricular Repolarization Indices - Displays proprietary repolarization information produced from signal processing.
- MyoVista Energy Category – Algorithm designed to detect repolarization abnormalities.
In addition to the proprietary informatics, the MyoVista spECG device also features the capabilities of a full featured 12-lead resting ECG including analysis using the Glasgow Algorithm, one of the world’s most respected interpretive algorithms. The MyoVista spECG device is not currently FDA cleared.
HeartSciences is a privately-held U.S. corporation based in Southlake, Texas.
For more information visit www.heartsciences.com.